The hedge fund made a counter-offer in March after Yesod Bio-Sciences’ proposed to take over for 15p per share
Redx Pharma PLC’s (LON:REDX) majority shareholder Redmile has increased its stake to 91.76% from 58.25%.
The hedge fund offered on 13 March to acquire the entire issued capital for 15.5p per share, with shareholders representing 33.51% of the pharma company agreeing to sell.
It was a counter-offer to Yesod Bio-Sciences’ proposal to take over for 15p per share, after the stock closed on 12 March at 4.5p.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE